Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Velvet Cichlid on its public offer for Sleep Cycle
Mandate

Vinge advises Velvet Cichlid on its public offer for Sleep Cycle

December 19, 2022 Life Sciences & Health

Velvet Cichlid has announced a public offer to the shareholders of Sleep Cycle AB (publ). The offer values the shares of Sleep Cycle at approximately SEK 862 million.

The Vinge team includes Jesper Schönbeck, Erik Sjöman, Linnéa Sellström, William Kåge, Emma Brolund, Philip Moré and Petter Hellgren (Capital Markets and Public M&A), Louise Brorsson Salomon and Seyran Sahin (Banking and Finance).

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025